2023
Immuno-chemotherapy as single treatment modality for larynx preservation (ICoLP): Co-primary endpoints and safety results.
Ferrarotto R, Johnson F, Hutcheson K, Sui D, Johnson J, Ebersole B, Mott F, Lewis C, Bonini F, Hoff C, Mitani Y, Cortez M, Bell D, El-Naggar A, Gunn G, Fuller C, Myers J, Lee J, Rosenthal D, Diaz E. Immuno-chemotherapy as single treatment modality for larynx preservation (ICoLP): Co-primary endpoints and safety results. Journal Of Clinical Oncology 2023, 41: 6008-6008. DOI: 10.1200/jco.2023.41.16_suppl.6008.Peer-Reviewed Original ResearchTreatment-related adverse eventsPathologic complete responseLarynx squamous cell carcinomaCo-primary endpointsEarly recurrenceCommon treatment-related adverse eventsStage IIDisease control rateLaryngeal preservation rateSolitary lung metastasisRelapse-free survivalSquamous cell carcinomaLoss of insuranceSingle treatment modalityAUC 6Eligible ptsEvaluable patientsImmuno-chemotherapyLarynx biopsiesDefinitive radiotherapyEfficacy endpointPrimary endpointRECIST 1.1Secondary endpointsAdverse events
2020
Surveillance Imaging for Patients with Head and Neck Cancer Treated with Definitive Radiotherapy: A Partially Observed Markov Decision Process Model
Ng S, Ajayi T, Schaefer A, Pollard C, Bahig H, Garden A, Rosenthal D, Gunn G, Phan J, Morrison W, Johnson J, Mohamed A, Sturgis E, Fuller C. Surveillance Imaging for Patients with Head and Neck Cancer Treated with Definitive Radiotherapy: A Partially Observed Markov Decision Process Model. International Journal Of Radiation Oncology • Biology • Physics 2020, 106: 1154. DOI: 10.1016/j.ijrobp.2019.11.234.Peer-Reviewed Original Research
2019
Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy
Ng S, Pollard C, Kamal M, Ayoub Z, Garden A, Bahig H, Gunn G, Frank S, Skinner H, Phan J, Berends J, Morrison W, Johnson J, Ferrarotto R, Sturgis E, Mohamed A, Lai S, Fuller C, Rosenthal D. Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy. Npj Precision Oncology 2019, 3: 22. PMID: 31583278, PMCID: PMC6764977, DOI: 10.1038/s41698-019-0097-y.Peer-Reviewed Original ResearchSecond primary malignanciesDefinitive radiotherapyFormer smokersCurrent smokersOverall survivalPrimary malignancyRisk of SPMCurative-intent therapyIndex oropharyngeal cancersCompletion of radiotherapySignificant smoking historyKaplan-Meier methodMajority of patientsNeck cancer patientsSame risk factorsNeck cancer treatmentEligible patientsSPM ratesPack yearsSmoking historyOropharyngeal cancerInvasive cancerCancer patientsRisk factorsClinical dataUsefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy
Ng S, Pollard C, Berends J, Ayoub Z, Kamal M, Garden A, Bahig H, Cantor S, Schaefer A, Ajayi T, Gunn G, Frank S, Skinner H, Phan J, Morrison W, Ferrarotto R, Johnson J, Mohamed A, Lai S, Hessel A, Sturgis E, Weber R, Fuller C, Rosenthal D. Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy. Cancer 2019, 125: 1823-1829. PMID: 30748005, PMCID: PMC7234834, DOI: 10.1002/cncr.31983.Peer-Reviewed Original ResearchConceptsDisease recurrenceAsymptomatic patientsOverall survivalClinical findingsNeck cancerAdverse clinical findingsLocoregional disease recurrenceMedian imaging followUsefulness of surveillanceDisease-free intervalMedian overall survivalDistant disease recurrenceGroup of patientsEfficacy of surveillanceTreatment of HNCEligible patientsSalvage therapySalvageable recurrenceDefinitive radiotherapyMedian timeSuspicious findingsPatientsRecurrenceRadiotherapyEarly detection
2018
Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer
Kamal M, Ng S, Eraj S, Rock C, Pham B, Messer J, Garden A, Morrison W, Phan J, Frank S, El-Naggar A, Johnson J, Ginsberg L, Ferrarotto R, Lewin J, Hutcheson K, Cardenas C, Zafereo M, Lai S, Hessel A, Weber R, Gunn G, Fuller C, Mohamed A, Rosenthal D. Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. Oral Oncology 2018, 79: 1-8. PMID: 29598944, PMCID: PMC5880303, DOI: 10.1016/j.oraloncology.2018.01.025.Peer-Reviewed Original ResearchConceptsTumor volumeOverall survivalLocal controlSurvival outcomesLimited invasionExtent of invasionLarynx cancerPrimary gross tumor volumeGood performance statusPoor local controlT3 laryngeal carcinomaImproved overall survivalLaryngeal carcinoma patientsMedian tumor volumeOverall survival rateIndependent prognostic factorPretreatment contrast-enhanced computed tomography imagesPrimary tumor invasionContrast-enhanced computed tomography imagesSoft tissue involvementLaryngeal preservation strategiesGross tumor volumeDefinitive radiotherapyExtent of involvementLaryngeal preservation
2017
Cost of surveillance imaging in head and neck cancer patients treated with definitive radiotherapy.
Ng S, Jomaa M, Pollard C, Ayoub Z, Mohamed A, Garden A, Berends J, Gunn G, Frank S, Skinner H, Phan J, Rosenthal D, Morrison W, Johnson J, Sturgis E, Lai S, Fuller C. Cost of surveillance imaging in head and neck cancer patients treated with definitive radiotherapy. Journal Of Clinical Oncology 2017, 35: 6610-6610. DOI: 10.1200/jco.2017.35.15_suppl.6610.Peer-Reviewed Original ResearchNeck cancer patientsSalvageable recurrenceAsymptomatic patientsDefinitive radiotherapyOverall survivalClinical findingsCancer patientsAdverse clinical findingsEarly salvage treatmentRecurrence-related deathsSuccessful salvage rateDisease-free intervalMedian overall survivalGroup of patientsChemotherapy useEligible patientsLR relapseSalvage therapyDistant relapseSalvage treatmentDisease recurrenceSalvage rateClinical outcomesMedian timeMean age